Menu
Not yet recruiting NCT07378605

Effect of Intraoperative Salbutamol Administration on Mechanical Power and Respiratory Mechanics in Obese Patients Undergoing Laparoscopic Bariatric Surgery

No phase Interventional Bariatric Surgery

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Salbutamol (Ventolin®), Normal Saline (0.9% Sodium Chloride).
Who it may be relevant to
Registry conditions: Bariatric Surgery. Basic parameters: 18 years — 65 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Turkey (Türkiye)
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

The primary objective of this study is to evaluate the effect of intraoperative salbutamol administration on mechanical power in obese patients undergoing laparoscopic bariatric surgery under general anesthesia. Mechanical power will be measured at predefined intraoperative time points (T0, T1, and T2), and changes over time will be compared to determine the impact of salbutamol on the overall energy delivered to the respiratory system during mechanical ventilation. Secondary objectives include the assessment of intraoperative respiratory mechanics, including peak airway pressure (Ppeak), plateau pressure (Pplat), driving pressure (Pdrive), airway resistance (Raw), and lung compliance, as well as gas exchange parameters (SpO₂, EtCO₂) and hemodynamic variables (mean arterial pressure). Postoperative pulmonary outcomes will be evaluated using the Melbourne Group Scale (MGS), with a score greater than 4 indicating the presence of postoperative pulmonary complications. The study aims to investigate whether improvement in intraoperative mechanical power and respiratory mechanics is associated with a reduction in postoperative pulmonary complications in this high-risk population.

Interventions

  • Drug Salbutamol (Ventolin®)
    Salbutamol will be administered intraoperatively via the respiratory circuit during mechanical ventilation to assess its effect on mechanical power and respiratory mechanics.
  • Drug Normal Saline (0.9% Sodium Chloride)
    Normal saline will be administered intraoperatively via the respiratory circuit in the same volume and manner as salbutamol to serve as a placebo

Primary outcome measures

  • Change in intraoperative mechanical power [Time frame: Baseline (intraoperative, after establishment of pneumoperitoneum and before Ventolin or saline administration)]
Secondary outcome measures (9)
  • Peak airway pressure (Ppeak) [Time frame: Baseline (intraoperative, after establishment of pneumoperitoneum and before Ventolin or saline administration)]
  • Plateau pressure (Pplat) [Time frame: Baseline (intraoperative, after establishment of pneumoperitoneum and before Ventolin or saline administration)]
  • Driving pressure (Pdrive) [Time frame: Baseline (intraoperative, after establishment of pneumoperitoneum and before Ventolin or saline administration)]
  • Airway resistance (Raw) [Time frame: Baseline (intraoperative, after establishment of pneumoperitoneum and before Ventolin or saline administration)]
  • Lung compliance [Time frame: Baseline (intraoperative, after establishment of pneumoperitoneum and before Ventolin or saline administration)]
  • Lung elastance (E) [Time frame: Baseline (intraoperative, after establishment of pneumoperitoneum and before Ventolin or saline administration)]
  • Heart rate (HR / Nabız) [Time frame: Baseline (intraoperative, after establishment of pneumoperitoneum and before Ventolin or saline administration)]
  • Mean arterial pressure (MAP) [Time frame: Baseline (intraoperative, after establishment of pneumoperitoneum and before Ventolin or saline administration)]
  • Postoperative pulmonary complications (Melbourne Group Scale >4) [Time frame: First assessment: Within 24 hours postoperatively Second assessment: 48 hours postoperatively Third assessment: Immediately before hospital discharge]

Eligibility criteria

Inclusion criteria

  • Age: 18-65 years

BMI ≥35 kg/m² (candidates for obesity surgery)

Scheduled for elective laparoscopic bariatric surgery

ASA physical status I-III

Signed informed consent

Exclusion criteria

Known allergy or contraindication to salbutamol

Severe cardiovascular disease (e.g., recent MI, uncontrolled arrhythmia)

Pre-existing severe pulmonary disease (e.g., severe COPD, asthma exacerbation)

Pregnancy or lactation

Emergency surgery

Use of β-agonists or bronchodilators within 24 hours prior to surgery

Patients with inability to provide informed consent

\-

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Double blind
Primary purpose
Prevention

Study locations

Turkey (Türkiye) · 1 center
  • Health Sciences University Gazi Yaşargil Training and Research Hospital — Kayapınar

Identifiers

NCT: NCT07378605 · Hts

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗